T2	location 72 77	China
T3	eligibility 82 104	advanced breast cancer
T5	total-participants 796 798	67
T7	intervention-participants 823 825	33
T8	control-participants 846 848	34
T9	outcome 920 943	complete remission (CR)
T10	intervention-participants 874 876	31
T11	iv-bin-abs 909 910	1
T12	iv-bin-abs 945 946	9
T13	outcome 956 978	partial remission (PR)
T14	iv-bin-abs 980 982	11
T15	outcome 987 1006	stable disease (SD)
T16	iv-bin-abs 1012 1014	10
T17	outcome 1019 1043	progressive disease (PD)
T18	outcome 1049 1068	total response rate
T19	iv-bin-percent 1073 1079	22.22%
T20	cv-bin-abs 1092 1093	1
T21	cv-bin-abs 1098 1099	5
T22	cv-bin-abs 1104 1106	19
T23	cv-bin-abs 1115 1116	9
T24	cv-bin-percent 1166 1172	15.15%
T25	outcome 1094 1096	CR
T26	outcome 1100 1102	PR
T27	outcome 1107 1109	SD
T28	outcome 1117 1119	PD
T29	outcome 1142 1161	total response rate
T30	outcome 1314 1351	median progression-free survival time
T31	iv-cont-median 1356 1366	6.2 months
T32	outcome 1386 1406	1-year survival rate
T33	iv-bin-percent 1411 1417	68.51%
T34	outcome 1427 1447	2-year survival rate
T35	iv-bin-percent 1452 1458	40.12%
T36	outcome 1482 1519	median progression-free survival time
T37	cv-cont-median 1524 1534	7.1 months
T38	outcome 1556 1576	1-year survival rate
T39	cv-bin-percent 1581 1587	65.23%
T40	outcome 1597 1617	2-year survival rate
T41	cv-bin-percent 1622 1628	39.71%
T42	outcome 1753 1817	myelosuppression, transient transaminase elevation, and alopecia
T43	outcome 1860 1884	severe allergic reaction
T44	iv-bin-abs 1819 1822	One
T45	cv-bin-abs 1901 1902	1
T46	outcome 1934 1950	whole body edema
T48	intervention 45 68	home-produced docetaxel
T49	outcome 1733 1747	adverse events
T1	control 546 559	control group
T4	control 612 616	Aisu
T47	intervention 598 608	Yiyoutasai
